BDX Stock Forecast & Price Target

Becton Dickinson's financial performance demonstrates strong foundational growth, highlighted by a 5.3% year-over-year sales increase in its Medical segment, which generated $888 million in FQ3'25, fueled by robust demand in Infusion Systems and Dispensing Solutions. The company's MedTech business has consistently achieved over 6% annual growth since the launch of its BD 2025 strategy, accompanied by improving profit margins. Furthermore, the MDS segment reported FY24 sales of $4.43 billion, reflecting a 3.2% year-over-year growth, underscoring the company's resilience in a competitive healthcare market.

Becton Dickinson's organic revenue growth outlook has been reduced to 3.0-3.5% year-over-year, down from the previously stated range of 4.0-4.5%, indicating a weakening financial forecast. In the most recent quarter, the company reported a 1.1% decline in sales year-over-year, largely driven by reduced demand in its Biosciences and Diagnostic Solutions segments. Additionally, the company faces significant challenges, including volume-based procurement headwinds in China and decreased government research funding affecting demand in the Biosciences sector, which collectively exert downward pressure on growth prospects.